Neutralizing antibodies and methods of use thereof
US7674884B2 · kind B2 · utility
12Cited by
9References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 14, 2005 |
| Grant date | Mar 9, 2010 |
| Priority date | — |
| Expiry date | Feb 28, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.